Navigation Links
Bio-Phase II 3.0mm Suture Anchor

ProductsBio-Phase II 3.0mm Suture Anchor
Company Arthrotek (A Biomet Company)
Item Bio-Phase II 3.0mm Suture Anchor
Features 
  • Anchor pull-out strength greater than #2 suture breakage
  • Suture easily slides through the anchor
  • Material disappears in 915 months
  • Strength retention throughout soft-tissue healing
    • Description LactoSorb copolymer is an absorbable co-polymer synthesized from all-natural ingredients: 82% L-Lactic acid and 18% glycolic acid. Unlike the homopolymers in common use such as 100% poly-L-lactic acid (PLLA) or 100% poly-glycolic acid (PGA), LactoSorb copolymer is substantially amorphous (without crystallinity), meaning that its degradation is uniform, precluding the crystalline release associated with degrading homopolymers that have been implicated in late inflammatory reactions. Furthermore, this co-polymer ratio permits the polymer to retain most of its strength for six to eight weeks, which is appropriate for healing, but not so long as to raise concerns about long-term stress shielding of bone. Mass loss, which always follows strength loss for absorbable polymers, occurs in a clinically relevant twelve months (approximately) for LactoSorb copolymer.
    Info Arthrotek (A Biomet Company)
    Customer Service: (800) 348-9500
    Web site: http://www.arthrotek.com

    Related medicine products :

    1. Bio-Phase II 2.0mm Suture Anchor
    2. 3.0mm Serrated Jaw Intraocular Forceps
    3. Serdarevic Suture Hook
    4. Castroviejo Suture Forceps
    5. OGawa Straight Suture-Fixation Forceps - 0.12 mm
    6. Colibri Suture Removal Forceps
    7. Paton Extra Delicate Suture Forceps
    8. Suture tying forceps
    9. Suture Removal Forceps #5a
    10. Micro Suture Forceps
    11. Suture Forceps
    Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8CBI Announces FDA Participation at Upcoming Forum on Clinical Trial Investigator Portals 14631 1CBI Announces FDA Participation at Upcoming Forum on Clinical Trial Investigator Portals 14631 2CBI Announces FDA Participation at Upcoming Forum on Clinical Trial Investigator Portals 14631 3Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 1Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 2Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 3Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 4Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 5Breast Health is a Year Round Priority 3A New Technology Identifies Risk of Breast Cancer in Younger Women 5779 1Breast Health is a Year Round Priority 3A New Technology Identifies Risk of Breast Cancer in Younger Women 5779 2Breast Health is a Year Round Priority 3A New Technology Identifies Risk of Breast Cancer in Younger Women 5779 3